AWARD-5 : Trulicity® vs sitagliptine,
en association à la metformine, sur 52 semaines 1
chez des patients diabétiques de type 2
AWARD: Assessment of Weekly AdministRation of dulaglutide in Diabetes
1. Nauck M, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-58.